C-Lab Outside
- A Gateway for
Biotech Innovation - C-Lab Outside, located at Samsung Biologics' Bio Campus II, is scheduled for completion in July 2027. As the first Korean location of Lilly Gateway Labs, the open innovation center will support Korean biotech companies in advancing innovative drug development and expanding their global reach.
- Expected Opening
- July 2027
- Resident Companies
- Up to 30
Eli Lilly and Company's
best-in-class innovation hub.
- Lilly Gateway Labs offers:
-
- Lilly’s global leading expertise
in innovative medicine. - Global networking opportunities.
- Biotech accelerator program, Catalyze360.
- Potential investment opportunities*.
- Lilly’s global leading expertise
C-Lab Outside: Samsung’s open innovation
program designed to support promising startups.
- C-Lab Outside offers:
-
- A leading global CDMO.
- Access to R&D infrastructure.
- Potential investment opportunities
through the Life Science Fund*. - Industry development initiatives.
*Opportunities are subject to each company’s independent investment criteria and due diligence.
Build for What’s Next
Supporting innovative biotech companies with Lilly’s world-class tailored programs and access to Samsung Biologics’ advanced research infrastructure and facilities.
-
2+2 Years
- Initial two-year residency with an option to extend for two more years
-
Mentoring
-
Access to mentoring opportunities with
Lilly experts
-
IR Day
- Global networking opportunities through various events
-
Catalyze 360
- Access to Lilly’s specialized biotech support program*
*Engagement with Catalyze360 is subject to a separate negotiated agreement.
Facilities
*Images shown are renderings of the planned facilities.
- Networking & Lounge Area
- Flexible Office Space
- Dedicated Laboratory Space
C-Lab Outside | five-story building with approx. 12,000 m² total floor area
- How To Apply
- C-Lab Outside at Samsung Biologics’ Bio Campus II will select up to 30 companies, from early-stage startups to pre-IPO biotech companies.
- Eligibility
- Early-stage startups to pre-IPO companies
Up to 30 companies - Therapeutic Areas
- Obesity, metabolic disease, immunology,
oncology, neuroscience, and more - Technology Areas
-
Innovative therapeutics, antibodies/ADCs, peptides,
AAVs, AI-enabled technologies, CGTs * Therapeutic and technology areas are not limited to those listed above. - Schedule
- Applications open in January 2027
Rolling applications thereafter - Process
- Joint review by Lilly and Samsung
Application → Review → Presentation → Final Selection - Residency
- Expected to begin in August 2027
Initial two years + extension of up to two additional years
Related Content